Lv5
1164 积分 2023-03-30 加入
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data
23小时前
已完结
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
1天前
已完结
Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression
1天前
求助中
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis
2天前
已完结
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis
6天前
已关闭
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis
6天前
已关闭
[Evolving treatment strategies for chronic graft-versus-host disease]
9天前
已关闭
Belumosudil for chronic graft-versus-host disease
9天前
已完结
Current trends and advances in the management of acquired Hemophilia A
10天前
已完结
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
22天前
已完结
皖公网安备34019202002308
